Form 144 Evolent Health, Inc. Filed by: Weinberg Jonathan

Go back to Form 144 Evolent Health, Inc. Filed by: Weinberg Jonathan

Truist Securities Reiterates Buy Rating on Evolent Health (EVH)

August 23, 2024 7:02 AM EDT

Truist Securities analyst Jailendra Singh reiterated a Buy rating and $33.00 price target on Evolent Health (NYSE: EVH).

The analyst comments "Bottom Line. M&A discussions related to EVH, whether in part of whole, is not a foreign discussion to the company. However, we... More